Половые гормоны и хронические заболевания почек у мужчин (литературный обзор)


И.А. Тюзиков

ООО “Медицинский центр диагностики и профилактики-плюс”, Ярославль
Обсуждаются клинические, эпидемиологические и патогенетические аспекты взаимосвязей между нарушениями обмена половых гормонов (андрогенов и эстрогенов) и хроническими заболеваниями почек у мужчин.

Литература



  1. Верткин А.Л., Пушкарь Д.Ю. Возрастной андрогенный дефицит и эректильная дисфункция. М.: ГЭОТАР-Медиа. 2009. 176 с.

  2. Калинченко С.Ю., Тюзиков И.А. Практическая андрология. М.: Практическая медицина. 2009. 400 с.

  3. GorbachinskyI., Akpinar H., Assimos D.G. Metabolic Syndrome and Urological Deseases. Rev. Urol. 2010; 12(4): 157—180.

  4. Kalyani R.R., Dobs A.S. Androgen deficiency, diabetes, and the metabolic syndrome in men. Curr. Opin. Endocrinol. Diabetes Obes. 2007; 14: 226-234.

  5. Abate N, Chandalia M., Cabo-Chan A.V.Jr. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int. 2004; 65: 386-392.

  6. Harvey A.M., Malvin R.L. The effect of androgenic hormones on creatinine secretion in the rats. J. Physiol. 1966; 184(4): 883-888.

  7. Handelsman D.J., Spaliviero J.A., Turtle J.R. Testicular function in experimental uremia. Endocrinology. 1985; 117(5): 1974-1983.

  8. Tanaka A., Kyokuwa M., Mori T. et al. Acceleration of renal dysfunction with ageing by the use of androgen in Wistar/Tw rats. In Vivo. 1995; 9(5): 495-502.

  9. Дедов И.И., Калинченко С.Ю. Возрастной андрогенный дефицит у мужчин. М.: Практическая медицина. 2006. 240 с.

  10. Вишневский Е.Л., Лоран О.Б., Пушкарь Д.Ю., Петров С.Б. Обструктивная ноктурия. М.: АНМИ. 2007. 162 с.

  11. Abrams P. Nocturia: the major problem in patients with LUTS suggestive of BPO. Eur. Urol. 2005; Suppl.; 3(6): 8-16.

  12. Cheng H.T., Huang J.W., Chiang C.K. et al. Metabolic syndrome and insulin resistance as risk factors for development of chronic kidney disease and rapid decline in renal function in elderly. J. Clin. Endocrinol. Metab. 2012; 97(4):1268-1276.

  13. Carrero J.J., Qureshi A.R., Parini P. et al. Low serum testosterone increases mortality risk among male dialysis patients. J. Am. Soc. Nephrol. 2009; 20(3): 613-620.

  14. Тюзиков И.А., Мартов А.Г. Системные метаболические факторы патогенеза заболеваний единственной почки у мужчин (пилотное исследование). Урология. 2012; 3:11-14.

  15. Grzegorczyk K., Krajewska M., Weyde W. et al. Gender and kidney diseases: the clinical importance and mechanisms of modifying effects. Postepy Hig. Med. Dosw (Online). 2011; 65: 849-857.

  16. NiemczykS., NiemczykL., Romejko-Ciepielewska K. Basic endocrinological disorders in chronic renal failure. Endokrynol. Pol. 2012; 63(3): 250-257.

  17. Albaaj F., Sivalingham M., Haynes P. et al. Prevalence of hypogonadism in male patients with renal failure. Postgrad. Med. J. 2006; 82(972): 693-696.

  18. Bellinghieri G., Santoro D., Mallamace A. et al. Sexual dysfunction in chronic renal failure. J. Nephrol. 2008; Suppl.13; 21:113-117.

  19. Yilmaz M.I., Sonmez A., Qureshi A.R. et al. Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease. Clin. J. Am. Soc.Nephrol. 2011; 6(7):1617-1625.

  20. Iglesias P., Carrero J.J., Di'ez J.J. Gonadal dysfunction in men with chronic kidney disease: clinical features, prognostic implications and therapeutic options. J. Nephrol. 2012; 25(1):31-42.

  21. Калинченко С.Ю., Тюзиков И.А. Метаболический синдром и уролитиаз (литературный обзор). Медицинский алфавит. Больница. 2011; 3: 33-40.

  22. Scales C.D.Jr., Curtis L.H., Norris R.D. Changing gender prevalence of stone disease. J. Urol. 2007; 177: 979-982.

  23. Blaak E. Gender differences in fat metabolism. Curr. Opin. Clin. Nutr. Metab. Care. 2001;4:499-502.

  24. Шустер П.И. Возрастной андрогенный дефицит - один из ведущих этиологических факторов уролитиаза у мужчин. Материалы IV Всероссийского Конгресса “Мужское здоровье”. М., 2008: 37-38.

  25. Taylor E.N., Stampfer M.J., Curhan G.C. Obesity, weight gain, and the risk of kidney stones. JAMA. 2005; 293: 455-462.

  26. Perez-Torres I., Guarner V., El Hafidi M., Banos G. Sex hormones, metabolic syndrome and kidney. Curr. Top. Med. Chem. 2011; 11(13):1694-1705.

  27. Pham H., Utzschneider K.M., de Boer I.H. Measurement of insulin resistance in chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 2011; 20(6): 640-646.

  28. Svartberg J., von Mohlen D., Schirmer H. Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Troms0 Study. Eur. J. Endocrinol. 2004;150: 65-71.

  29. Traish A.M., Saad F., Guay A. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J. Androl. 2009; 30: 23-32.

  30. Sakhaee K. Nephrolithiasis as a systemic disorder. Curr. Opin. Nephrol. Hypertens. 2008; 17: 304-309.

  31. Lu Y., Fu Y., Ge Y. et al. The vasodilatory effect of testosterone on renal afferent arterioles. Gend. Med. 2012; 9(2):103-111.

  32. Ferrucci L., Maggio M., Bandinelli S. et al. Low testosterone levels and the risk of anemia in older men and women. Arch. Intern Med. 2006; 166 (13):1380-1388.

  33. Rodrigo R., Rivera G. Renal damage mediated by oxidative stress: a hypothesis of protective effects of red wine. Free Radical. Biol. Med. 2002; Vol. 33; 3:409-422.

  34. Sahovic V., Sahovic S., Grosa E. et al. Correlation between parathormone and sexual hormones in patients on haemodialysis. Med. Arh. 2012; 66(3):177-180.

  35. Shen Y., Liu F., Li Q. et al. The gonadal hormone regulates the plasma lactate levels in type 2 diabetes treated with and without metformin. Diabetes Technol Ther. 2012; 14(6): 469-474.

  36. Brismar K., Nilsson S.E. Interrelations and associations of serum levels of steroids and pituitary hormones with markers of insulin resistance, inflammatory activity, and renal function in men and women aged >70 years in an 8-year longitudinal study of opposite-sex twins. Gend. Med. 2009; Suppl. 1; 6:123-136.

  37. Yi S., Selvin E., Rohrmann S. et al. Endogenous sex steroid hormones and measures of chronic kidney disease (CKD) in a nationally representative sample of men. Clin. Endocrinol. (Oxf). 2009; 71(2):246-252.

  38. Silbiger S.R., Neugarten J. The impact of gender on the progression of chronic renal disease. Am. J. Kidney Dis. 1995; 25: 515-533.

  39. Silbiger S., Neugarten J. Gender and human chronic renal disease. Gend. Med. 2008; Suppl. A; 5: 3-10.

  40. Kittikulsuth W., Sullivan J.C., Pollock D.M. ET-1 actions in the kidney: evidence for sex differences. Br. J. Pharmacol. 2012; Feb 28.doi: 10.1111/j.1476-5381.2012.01922.x. [Epub ahead of print].

  41. Gafter U., Ben-Bassat M., Levi J. Castration inhibits glomerular hypertrophy and proteinuria in uninephrectomized male rats. Eur. J. Clin. Invest. 1990; 20: 360-365.

  42. Ji H., Menini S., Mok K. et al. Gonadal steroid regulation of renal injury in renal wrap hypertension. Am. J. Physiol. Renal Physiol. 2005; 288: 513-520.

  43. Robert R., Ghazali D.A., Favreau F. et al. Gender difference and sex hormone production in rodent renal ischemia reperfusion injury and repair. J. Inflamm. (Lond). 2011; 8: 14.

  44. Haring R., Nauck M., Volzke H. et al. Low serum testosterone is associated with increased mortality in men with stage 3 or greater nephropathy. Am. J. Nephrol. 2011; 33(3): 209-217.

  45. Gungor O., Kircelli F., Carrero J.J. et al. Endogenous testosterone and mortality in male hemodialysis patients: is it the result of aging? Clin. J. Am. Soc. Nephrol. 2010; 5(11): 2018-2023.

  46. Sandberg K. Mechanisms underlying sex differences in progressive renal disease. Gend. Med. 2008; 5: 10-23.

  47. Schmidt R.J., Baylis C. Total nitric oxide production is low in patients with chronic renal disease. Kidney Int. 2000; 58: 1261-1266.

  48. Schmidt R.J., Yokota S., Tracy T.S. et al. Nitric oxide production is low in end-stage renal disease patients on peritoneal dialysis. Am. J. Physiol. 1999; 276: 794-797.

  49. Erdely A., Greenfeld Z., Wagner L., Baylis C. Sexual dimorphism in the aging kidney: Effects on injury and nitric oxide system. Kidney Int. 2003; 63: 1021-1026.

  50. Metcalfe P.D., Meldrum K.K. Sex dijferences and the role of sex steroids in renal injury. J. Urol. 2006; 176: 15-21.

  51. Reckelhoff J.F., Hennington B.S., Moore A.G. et al. Gender differences in the renal nitric oxide (NO) system: dissociation between expression of endothelial NO synthase and renal hemodynamic response to NO synthase inhibition. Am. J. Hypertens. 1998; 11: 97-104.

  52. Dubey R.K., Gillespie D.G., Keller P.J. et al. Role of methoxyestradiols in the growth inhibitory effects of estradiol on human glomerular mesangial cells. Hypertension. 2002; 39: 418-424.

  53. Matsuda T., Yamamoto T., Muraguchi A., Saatcioglu F.: Cross-talk between transforming growth factor-b and estrogen receptor signaling through Smad3. J. Biol. Chem. 2001; 276: 42908-42914.

  54. Maric C., Enright C., Bhatti F. et al. 17b-Estradiol attenuates ANG II-induced cell proliferation and ECM synthesis in renal interstitial fibroblasts. Am. J. Physiol. Endocrinol. Metab. 2003; 285: 812-818.

  55. Lee J.C., Laydon J.T., McDonnell P.C. et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature. 1994; 372: 739-746.

  56. Elliot S.J., Berho M., Korach K. et al. Gender-specific effects of endogenous testosterone: female a-estrogen receptor-deficient C57BI/6J mice develop glomeruloscle—rosis. Kidney Int. 2007; 72: 464-472.

  57. Elliot S.J., Karl M., Berho M. et al. Estrogen deficiency accelerates progression of glomerulosclerosis in susceptible mice. Am. J. Pathol. 2003; 162: 1441-1448.

  58. Schiffer M., Bitzer M., Roberts I.S. et al. Apoptosis in podocytes induced by TGF-b and Smad7. J. Clin. Invest. 2001; 108: 807-816.

  59. McLachlan M.S., Guthrie J.C., Anderson C.K., Fulker M.J. Vascular and glomerular changes in the ageing kidney. J. Pathol. 1977; 121: 65-78.

  60. Kotzin B.L. Systemic lupus erythematosus. Cell. 1996; 85: 303-306.

  61. Yacoub Wasef S.Z. Gender differences in systemic lupus erythematosus. Gend. Med. 2004; 1: 12-17.

  62. Peeva E., Michael D., Cleary J. et al. Prolactin modulates the naive B cell repertoire. J. Clin. Invest. 2003; 111: 275-283.

  63. Modlinger P., Chabrashvili T., Gill P.S. et al. RNA silencing in vivo reveals role of p22phox in rat angiotensin slow pressor response. Hypertension. 2006; 47: 238-244.

  64. Stern R., Fishman J., Brusman H., Kunkel H.G. Systemic lupus erythematosus associated with Klinefelter’s syndrome. Arthritis Rheum. 1977; 20: 18-22.

  65. Petri M.A., Mease P.J., Merrill J.T. et al. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum. 2004; 50: 2858-2868.

  66. Oelkers W.K. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids. 1996; 61: 166-171.

  67. Eriksen B.O., Ingebretsen O.C. The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age. Kidney Int. 2006; 69: 375-382.

  68. Neugarten J., Acharya A., Silbiger S.R. Effect of gender on the progression of nondiabetic renal disease: a meta-analysis. J. Am. Soc. Nephrol. 2000; 11: 319-329.

  69. Jafar T.H., Schmid C.H., Stark P.C. et al. The rate of progression of renal disease may not be slower in women compared with men: a patient meta­analysis. Nephrol. Dial. Transplant. 2003; 18: 2047-2053.

  70. Jafar T.H., Stark P.C., Schmid C.H. et al. AIPRD Study Group: Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann. Intern. Med. 2003; 139: 242-252.

  71. Stringer K.D., Komers R., OsmanS.A. et al. Gender hormones and the progression of experimental polycystic kidney disease. Kidney Int. 2005; 68: 1729-1739.

  72. Johnson A.M., Gabow P.A. Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease. J. Am. Soc. Nephrol. 1997; 8: 1560-1567.

  73. Stewart J.H. End-stage renal failure appears earlier in men than in women with polycystic kidney disease. Am. J. Kidney Dis. 1994; 24: 181-183.

  74. Mankhey R.W., Bhatti F., Maric C. 17b-Estradiol replacement improves renal function and pathology associated with diabetic nephropathy. Am. J. Physiol. Renal Physiol. 2005; 288: 399-405.

  75. Garza R., Medina R., Basu S., Pugh J.A. Predictors of the rate of renal function decline in non-insulin-dependent diabetes mellitus. Am. J. Nephrol. 1997; 17: 59-67.

  76. Jacobsen P., Rossing K., Tarnow L. et al. Progression of diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int. 1999; Suppl.; 71: 101-105.

  77. Harris M.I., Flegal K.M., Cowie C.C. et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998; 21: 518-524.

  78. Castellano J.M., Navarro V.M., Fernandez-Fernandez R. et al. Expression of hypothalamic KiSS-1 system and rescue of defective gonadotropic responses by kisspeptin in streptozotocin-induced dia—betic male rats. Diabetes. 2006; 55: 2602-2610.

  79. Xu Q., Wells C.C., Garman J.H. et al. Imbalance in sex hormone levels exacerbates diabetic renal disease. Hypertension. 2008; 51: 1218-1224.

  80. Natoli A.K., Medley T.L., Ahimastos A.A. et al. Sex steroids modulate human aortic smooth muscle cell matrix protein deposition and matrix metalloproteinase expression. Hypertension. 2005; 46: 1129-1134.

  81. Reckelhoff J.F.: Gender differences in the regulation of blood pressure. Hypertension. 2001; 37: 1199-1208.

  82. Kang A.K., Miller J.A.: Effects of gender on the renin-angiotensin system, blood pressure, and renal function. Curr. Hypertens. Rep. 2002; 4: 143-151.

  83. Woods L.L., Morgan T.K., Resko J.A. Castration fails to prevent prenatally programmed hypertension in male rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2010; 298(4):1111-1116.

  84. Hu J., Tan S., Zhong Y. Effects of testosterone on renal function in salt- loaded rats. Am. J. Med. Sci. 2011; 342(1):38-43.

  85. Afsar B., Ay M., Burucu R. et al. The relationship between serum total testosterone and 24-hour urinary sodium excretion in never-treated stage 1 essential hypertensive patients. Turk. Kardiyol. Dern. Ars. 2012; 40(4):316-322.


Об авторах / Для корреспонденции


Тюзиков И.А. – ООО “Медицинский центр диагностики и профилактики-плюс”, к.м.н.
Е-mail: phoenix-67@list.ru


Похожие статьи


Бионика Медиа